NCT04416984 - Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

May 31, 2029

Conditions

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions

GENETIC

ALLO-501A

ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

Trial Locations (23)

3065

St. Vincent's Hospital Melbourne, Fitzroy

3168

Monash Medical Centre, Clayton

4102

Princess Alexandra Hospital, Woolloongabba

15212

Allegheny General Hospital, Pittsburgh

30342

Northside Hospital - Atlanta, Atlanta

30912

Augusta University, Augusta

33136

University of Miami, Miami

37232

Vanderbilt Ingram Cancer Center, Nashville

40207

Norton Cancer Institute, Louisville

53226

Medical College of Wisconsin, Milwaukee

75251

Texas Oncology, Dallas

77030

MD Anderson Cancer Center - University of Texas, Houston

78704

St. David's South Austin Medical Center, Austin

85054

Mayo Clinic Hospital, Phoenix

85234

Banner MD Anderson Cancer Center, Gilbert

90095

UCLA Medical Center, Los Angeles

91010

City of Hope, Duarte

94035

Stanford Cancer Institute, Palo Alto

80218-1234

Colorado Blood Cancer Institute, Denver

06510

Advent Health, Orlando

33612-9416

Moffitt Cancer Center, Tampa

B3H 2Y9

QEII Health Sciences Centre-VG Site, Halifax

G1J 1Z4

CHU de Québec -Université Laval; Hôpital de l'Enfant-Jésus, Québec